Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia

NCT03504644 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT03504644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03504644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 13, 2018
Completion date
December 31, 2028
Enrollment
40 (actual)
Sites
170

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult lymphoblastic lymphoma, recurrent b acute lymphoblastic leukemia, recurrent b lymphoblastic lymphoma, recurrent t acute lymphoblastic leukemia, recurrent t lymphoblastic lymphoma, refractory b acute lymphoblastic leukemia, refractory b lymphoblastic lymphoma, refractory t acute lymphoblastic leukemia, refractory t lymphoblastic lymphoma